Core Viewpoint - Grail's stock experienced a significant decline, losing more than half its value following a failed trial of its Galleri early-detection cancer test, which did not meet its primary endpoint [1] Group 1: Company Performance - Grail's shares were the biggest losers on the Nasdaq, reflecting investor disappointment after the trial results [1] - The stock price had nearly doubled over the past year due to high expectations for strong trial results [1] Group 2: Industry Impact - Illumina, a major shareholder in Grail, also saw its stock take a hit as a result of the failed trial [1]

Grail (GRAL) shares were cut in half on Feb. 20 after the biotech firm said its highly anticipated NHS-Galleri clinical trial failed to meet its primary endpoint. As retail and institutional investors bailed on GRAL today, its 14-day relative strength index (RSI) crashed to 24, indicating a technical rebound was likely in the near term. More News from Barchart Still, investors are recommended against buying the dip in Grail stock, even though it looks like a bargain at about $49. www.barchart.com Sho ...

Core Viewpoint - Exelixis has been gaining recognition in the biotech sector over the past five years, driven by strong financial performance and growth potential, particularly through its cancer drug Cabometyx [1] Financial Performance - Exelixis has shown solid financial results with increasing revenue, earnings, and free cash flow over the past five years, slightly outperforming the S&P 500 during this period [3] Product Success - The success of Exelixis is largely attributed to Cabometyx, which is the top-prescribed cancer drug for renal cell carcinoma and has received multiple label expansions, including combination treatments with established drugs like Bristol Myers Squibb's Opdivo [2] Future Prospects - Exelixis is preparing for potential challenges as Cabometyx may face generic competition by early 2030, but the drug is expected to maintain its market position until then [4] - In March 2025, Cabometyx received approval for treating previously treated advanced neuroendocrine tumors, expanding its market reach [5] Pipeline Development - To mitigate reliance on Cabometyx, Exelixis is developing zanzalintinib, which has completed a phase 3 study for metastatic colorectal cancer, an area with significant unmet medical needs [6] - The company has requested regulatory approval for zanzalintinib in colorectal cancer and plans to explore additional indications, alongside other pipeline candidates that may progress clinically in the coming years [7]

2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with rare diseases, today announced financial results for the full year ended Decemb ...

VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the "Offering") of 7,607,145 common shares of the Company (the “Common Shares"), whi ...

This isn't a good day for investors in Grail (NASDAQ: GRAL). The stock declined more than 50% by 1:30 p.m. today. The move comes on the day of its fourth-quarter earnings results, but more importantly, the release of its top-line results from a major trial of its Galleri multi-cancer early detection (MCED) test in England's National Health Service (NHS). As you have already surmised, the trial did not go as planned. What went wrong The first bullet point of the results release is what investors are focusi ...

CRISPR Therapeutics (NASDAQ: CRSP) already has notable achievements under its belt. For instance, it developed Casgevy, a medicine for a pair of rare blood diseases, which became the first gene-editing therapy to use the famous, Nobel Prize-winning CRISPR gene-editing system to earn approval. CRISPR Therapeutics has lagged the market since that breakthrough, but with some highly promising gene-editing medicines in its pipeline and potential upcoming catalysts, some investors are excited about the biotech's ...

Key Takeaways Prothena reported a Q4 loss of 45 cents per share, while revenues fell sharply year over year.Prothena expects 2026 net cash burn of $50M-$55M and projects up to $105M in milestone payments.Prothena's partnered pipeline includes late-stage studies with Roche and Novo Nordisk through 2029.Prothena Corporation (PRTA) reported fourth-quarter 2025 adjusted loss per share (excluding restructuring costs) of 45 cents, in line with the Zacks Consensus Estimate.In the year-ago quarter, the company had ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported a wider-than-expected loss for the fourth quarter on Thursday.The company posted quarterly losses of $3.50 per share which missed the analyst consensus estimate of losses of $3.08 per share.Praxis Precision Medicine shares fell 0.1% to trade at $303.00 on Friday.These analysts made changes to their price targets on Praxis Precision Medicine following earnings announcement.Wedbush analyst Laura Chico maintained Praxis Precision Medicine with an Underper ...

Key Takeaways Insmed posted a wider Q4 loss of $1.54 per share as revenues jumped 153% to $263.8M.Brinsupri delivered $144.6M in Q4 sales; 2026 guidance calls for at least $1B.Arikayce sales rose 14% to $119.2M; R&D and SG&A expenses climbed sharply.Insmed (INSM) reported a fourth-quarter 2025 loss of $1.54 per share, wider than the Zacks Consensus Estimate of a loss of $1.07. In the year-ago quarter, the company had incurred a loss of $1.32.Quarterly revenues rose 153% year over year to over $263.8 million ...